BET inhibitors attenuate cell growth and survival in several hematologic cancer models [44], but also in pancreatic cancer models [45], at least in part through the down-regulation of the critical oncogene MYC. Here, MYC is linked to hematopoietic and lymphoid cell neoplasm.